Analysis of genomic information and biological characteristics of a bacteriophage against methicillin-resistant Staphylococcus aureus in patients with median sternal incision infection
-
摘要:
目的 分离提纯1株新型耐甲氧西林金黄色葡萄球菌（MRSA）的噬菌体，并对其基因组学信息和生物学特性进行分析。 方法 采用实验研究方法。取分离自陆军军医大学（第三军医大学）第二附属医院收治的1例胸骨正中切口感染的63岁女性患者创面的MRSA（下称宿主菌）液，采用污水共培养法和双层琼脂平板法从该院污水中分离提纯得到噬菌体，并命名为噬菌体SAP23，观察噬菌斑形态。采用磷钨酸负染法将噬菌体SAP23染色，采用透射电子显微镜观察其形态。采用十二烷基磺酸钠/蛋白酶裂解方案制备噬菌体SAP23 DNA，在Illumina NovaSeq PE150平台下进行全基因组测序，并完成序列组装、注释、系统发生树等基因组学分析。将噬菌体SAP23液分别按10.000 0、1.000 0、0.100 0、0.010 0、0.001 0、0.000 1感染复数与宿主菌液共培养4 h后，采用点滴法测定噬菌体效价，筛选最佳感染复数，此处及以下样本数均为3。按测得的最佳感染复数取噬菌体SAP23液与宿主菌液分别共同孵育5、10、15 min后，同前测定噬菌体效价，筛选最佳吸附时间。按测得的最佳感染复数取噬菌体SAP23液与宿主菌液按最佳吸附时间孵育后，分别于培养0（即刻）、5、10、15、20、30、40、50、60、80、100、120 min，同前测定噬菌体效价，绘制一步生长曲线。取噬菌体SAP23液分别在温度为4、37、50、60、70、80 ℃下，在pH值为2、3、4、5、6、7、8、9、10、11、12下孵育1 h，测定稳定性。取陆军军医大学（第三军医大学）微生物教研室储存的41株MRSA，完成噬菌体SAP23的宿主谱范围检测。 结果 噬菌体SAP23能在宿主菌双层琼脂板上形成透明噬菌斑。噬菌体SAP23头部是直径为（88±4）nm的多面体，其尾部长度为（279±21）nm、宽度为（22.6±2.6）nm。噬菌体SAP23基因组为全长151 618 bp的线状双链DNA，序列两端有11 681 bp的长末端重复序列，预测出220个开放阅读框，噬菌体可编码4个转运RNA，未预测出毒力因子或抗性基因，注释功能的噬菌体SAP23基因可分为5个组，GenBank登录号为MZ427930，噬菌体SAP23全基因组序列与共线性分析中的6个葡萄球菌噬菌体全基因组序列有5个局部共线区域，但在局部共线区域内部或外部存在差异。噬菌体SAP23属于Herelleviridae科Twortvirinae亚科Kayvirus病毒属。噬菌体SAP23的最佳感染复数为0.010 0，最佳吸附时间为10 min，潜伏期约为20 min，裂解期约为80 min；在4~37 ℃温度条件及pH值为4~9的条件中，稳定性较好。噬菌体SAP23可裂解41株MRSA中的3株。 结论 噬菌体SAP23为Herelleviridae科Twortvirinae亚科Kayvirus病毒属成员，潜伏期短，其对温度和酸碱耐受性好，可有效裂解MRSA，为不含毒力因子和抗性基因的新型烈性窄谱噬菌体。 -
关键词:
- 耐甲氧西林金黄色葡萄球菌 /
- 细菌噬菌体 /
- 基因组学 /
- 伤口感染 /
- 生物学特性
Abstract:Objective To isolate and purify a bacteriophage against methicillin-resistant Staphylococcus aureus (MRSA), and to analyze its genomic information and biological characteristics. Methods The experimental research methods were adopted. MRSA (hereinafter referred to as host bacteria) solution was collected from the wound of a 63-year-old female patient with the median sternum incision infection admitted to the Second Affiliated Hospital of Army Medical University (the Third Military Medical University). The bacteriophage, named bacteriophage SAP23 was isolated and purified from the sewage of the Hospital by sewage co-culture method and double-layer agar plate method, and the plaque morphology was observed. The morphology of bacteriophage SAP23 was observed by transmission electron microscope after phosphotungstic acid negative staining. The whole genome of bacteriophage SAP23 was sequenced with NovaSeq PE15 platform after its DNA was prepared by sodium dodecyl sulfonate/protease cleavage scheme, and genomic analysis including sequence assembly, annotation, and phylogenetic tree were completed. The bacteriophage SAP23 solution was co-incubated with the host bacterial solution for 4 h at the multiplicity of infection (MOI) of 10.000 0, 1.000 0, 0.100 0, 0.010 0, 0.001 0, and 0.000 1, respectively, and then the bacteriophage titer was measured by the drip plate method to select the optimal MOI, with here and the following sample numbers of 3. The bacteriophage SAP23 solution was co-incubated with the host bacterial solution at the optimal MOI for 5, 10, and 15 min, respectively, and the bacteriophage titer was measured by the same method as mentioned above to select the optimal adsorption time. After the bacteriophage SAP23 solution was co-incubated with the host bacterial solution at the optimal MOI for the optimal adsorption time, the bacteriophage titers were measured by the same method as mentioned above at 0 (immediately), 5, 10, 15, 20, 30, 40, 50, 60, 80, 100, and 120 min after culture, respectively, and a one-step growth curve was drawn. The bacteriophage SAP23 solution was incubated at 4, 37, 50, 60, 70, and 80 ℃ and pH 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 for 1 h, respectively, to determine its stability. A total of 41 MRSA strains stored in the Department of Microbiology of Army Medical University (the Third Military Medical University) were used to determine the host spectrum of bacteriophage SAP23. Results The bacteriophage SAP23 could form a transparent plaque on the host bacteria double-layer agar plate. The bacteriophage SAP23 has a polyhedral head with (88±4) nm in diameter and a tail with (279±21) nm in length and (22.6±2.6) nm in width. The bacteriophage SAP23 has a linear, double-stranded DNA with a full length of 151 618 bp and 11 681 bp long terminal repeats sequence in the sequence ends. There were 220 open reading frames predicted and the bacteriophage could encode 4 transfer RNAs, while no resistance genes or virulence factors were found. The annotation function of bacteriophage SAP23 genes could be divided into 5 groups. The GenBank accession number was MZ427930. According to the genomic collinearity analysis, there were 5 local collinear blocks in the whole genome between the bacteriophage SAP23 and the chosen 6 Staphylococcus bacteriophages, while within or outside the local collinear region, there were still some differences. The bacteriophage SAP23 belonged to the Herelleviridae family, Twortvirinae subfamily, and Kayvirus genus. The optimal MOI of bacteriophage SAP23 was 0.010 0, and the optimal adsorption time was 10 min. The bacteriophage SAP23 had a latent period of 20 min, and a growth phase of 80 min. The bacteriophage SAP23 was able to remain stable at the temperature between 4 and 37 ℃ and at the pH values between 4 and 9. The bacteriophage SAP23 could lyse 3 of the 41 tested MRSA strains. Conclusions The bacteriophage SAP23 is a member of the Herelleviridae family, Twortvirinae subfamily, and Kayvirus genus. The bacteriophage SAP23 has a good tolerance for temperature and acid-base and a short latent period, and can lyse MRSA effectively. The bacteriophage SAP23 is a new type of potent narrow-spectrum bacteriophage without virulence factors and resistance genes. -
参考文献
(63) [1] WangPH, HuangBS, HorngHC, et al.Wound healing[J].J Chin Med Assoc,2018, 81(2):94-101. DOI: 10.1016/j.jcma.2017.11.002. [2] WilkinsonHN, HardmanMJ.Wound healing: cellular mechanisms and pathological outcomes[J].Open Biol,2020, 10(9):200223. DOI: 10.1098/rsob.200223. [3] SarhanWA, AzzazyHME, El-SherbinyIM.Honey/chitosan nanofiber wound dressing enriched with allium sativum and cleome droserifolia: enhanced antimicrobial and wound healing activity[J].ACS Appl Mater Interfaces,2016, 8(10):6379-6390. DOI: 10.1021/acsami.6b00739. [4] HanG, CeilleyR.Chronic wound healing: a review of current management and treatments[J].Adv Ther,2017, 34(3):599-610. DOI: 10.1007/s12325-017-0478-y. [5] SiddiquiAR,BernsteinJM.Chronic wound infection: facts and controversies[J].Clin Dermatol,2010,28(5):519-526.DOI: 10.1016/j.clindermatol.2010.03.009. [6] LakhundiS, ZhangKY. Methicillin-resistant Staphylococcus aureus: molecular characterization, evolution, and epidemiology[J].Clin Microbiol Rev,2018,31(4):e0020-18.DOI: 10.1128/CMR.00020-18. [7] SongRh,YuB,FriedrichD,et al.Naphthoquinone-derivative as a synthetic compound to overcome the antibiotic resistance of methicillin-resistant S. aureus[J].Commun Biol,2020,3(1):529.DOI: 10.1038/s42003-020-01261-0. [8] Hernández-AristizábalI, Ocampo-IbáñezID.Antimicrobial peptides with antibacterial activity against vancomycin-resistant Staphylococcus aureus strains: classification, structures, and mechanisms of action[J].Int J Mol Sci,2021, 22(15):7927. DOI: 10.3390/ijms22157927. [9] CrockerTF, BrownL, LamN, et al. Information provision for stroke survivors and their carers[J].Cochrane Database Syst Rev,2021,11(11):CD001919.DOI: 10.1002/14651858.CD001919.pub4. [10] CisekAA, DąbrowskaI, GregorczykKP, et al.Phage therapy in bacterial infections treatment: one hundred years after the discovery of bacteriophages[J].Curr Microbiol,2017, 74(2):277-283. DOI: 10.1007/s00284-016-1166-x. [11] KortrightKE, ChanBK, KoffJL, et al.Phage therapy: a renewed approach to combat antibiotic-resistant bacteria[J].Cell Host Microbe,2019, 25(2):219-232. DOI: 10.1016/j.chom.2019.01.014. [12] SummersWC.The strange history of phage therapy[J].Bacteriophage,2012, 2(2):130-133. DOI: 10.4161/bact.20757. [13] SarkerSA,SultanaS,ReutelerG,et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh[J].EBioMedicine,2016,4:124-137.DOI: 10.1016/j.ebiom.2015.12.023. [14] FurfaroLL, PayneMS, ChangBJ.Bacteriophage therapy: clinical trials and regulatory hurdles[J].Front Cell Infect Microbiol,2018, 8:376. DOI: 10.3389/fcimb.2018.00376. [15] JaultP,LeclercT,JennesS,et al.Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial[J].Lancet Infect Dis,2019,19(1):35-45.DOI: 10.1016/S1473-3099(18)30482-1. [16] LeitnerL, UjmajuridzeA, ChanishviliN, et al.Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial[J].Lancet Infect Dis,2021,21(3):427-436.DOI: 10.1016/S1473-3099(20)30330-3. [17] CarvalhoC, CostaAR, SilvaF, et al.Bacteriophages and their derivatives for the treatment and control of food-producing animal infections[J].Crit Rev Microbiol,2017,43(5):583-601.DOI: 10.1080/1040841X.2016.1271309. [18] MichelsonD, GrundmanM, MagnusonK, et al.Randomized, placebo controlled trial of NPT088, a phage-derived, amyloid-targeted treatment for Alzheimer's disease[J].J Prev Alzheimers Dis,2019, 6(4):228-231. DOI: 10.14283/jpad.2019.37. [19] YangZC, LiuXZ, ShiYL, et al.Characterization and genome annotation of a newly detected bacteriophage infecting multidrug-resistant Acinetobacter baumannii[J].Arch Virol,2019,164(6):1527-1533.DOI: 10.1007/s00705-019-04213-0. [20] LuSG, LeS,TanYL, et al.Genomic and proteomic analyses of the terminally redundant genome of the Pseudomonas aeruginosa phage PaP1: establishment of genus PaP1-like phages[J].PLoS One,2013,8(5):e62933.DOI: 10.1371/journal.pone.0062933. [21] GarneauJR, DepardieuF, FortierLC, et al.PhageTerm: a tool for fast and accurate determination of phage termini and packaging mechanism using next-generation sequencing data[J].Sci Rep,2017,7(1):8292.DOI: 10.1038/s41598-017-07910-5. [22] BesemerJ,LomsadzeA,BorodovskyM.GeneMarkS: a self-training method for prediction of gene starts in microbial genomes. Implications for finding sequence motifs in regulatory regions[J].Nucleic Acids Res,2001,29(12):2607-2618.DOI: 10.1093/nar/29.12.2607. [23] BrettinT,DavisJJ,DiszT,et al.RASTtk: a modular and extensible implementation of the RAST algorithm for building custom annotation pipelines and annotating batches of genomes[J].Sci Rep,2015,5:8365.DOI: 10.1038/srep08365. [24] AzizRK,BartelsD,BestAA,et al.The RAST Server: rapid annotations using subsystems technology[J].BMC Genomics,2008,9:75.DOI: 10.1186/1471-2164-9-75. [25] ArndtD,GrantJR,MarcuA,et al. PHASTER: a better, faster version of the PHAST phage search tool[J].Nucleic Acids Res,2016,44(W1):W16-21.DOI: 10.1093/nar/gkw387. [26] LoweTM, EddySR. tRNAscan-SE: a program for improved detection of transfer RNA genes in genomic sequence[J].Nucleic Acids Res,1997,25(5):955-964.DOI: 10.1093/nar/25.5.955. [27] LagesenK,HallinP,RødlandEA,et al.RNAmmer: consistent and rapid annotation of ribosomal RNA genes[J].Nucleic Acids Res,2007,35(9):3100-3108.DOI: 10.1093/nar/gkm160. [28] DarlingACE, MauB, BlattnerFR,et al. Mauve: multiple alignment of conserved genomic sequence with rearrangements[J].Genome Res,2004,14(7):1394-1403.DOI: 10.1101/gr.2289704. [29] AnisimovaM.Evolutionary genomics: statistical and computational methods[M]. New York: Springer New York,2019: 121-147. [30] El-ArabiTF,GriffithsMW,SheYM,et al.Genome sequence and analysis of a broad-host range lytic bacteriophage that infects the Bacillus cereus group[J].Virol J,2013,10:48.DOI: 10.1186/1743-422X-10-48. [31] 吴丽飞,王兆飞,王中华,等.高效裂解多重耐药金黄色葡萄球菌的噬菌体分离及裂解酶的制备[J].中国动物传染病学报,2021,29(3):1-9. DOI: 10.19958/j.cnki.cn31-2031/s.2021.03.001. [32] YangS,YangY,CuiSX,et al.Chitosan-polyvinyl alcohol nanoscale liquid film-forming system facilitates MRSA-infected wound healing by enhancing antibacterial and antibiofilm properties[J].Int J Nanomedicine,2018,13:4987-5002.DOI: 10.2147/IJN.S161680. [33] DouJL, JiangYW, XieJQ, et al.New is old, and old is new: recent advances in antibiotic-based, antibiotic-free and ethnomedical treatments against methicillin-resistant Staphylococcus aureus wound infections[J].Int J Mol Sci,2016, 17(5):617. DOI: 10.3390/ijms17050617. [34] MaciejewskaB,OlszakT,Drulis-KawaZ.Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: an ambitious and also a realistic application?[J].Appl Microbiol Biotechnol,2018,102(6):2563-2581.DOI: 10.1007/s00253-018-8811-1. [35] MorozovaVV, VlassovVV, TikunovaNV.Applications of bacteriophages in the treatment of localized infections in humans[J].Front Microbiol,2018, 9:1696. DOI: 10.3389/fmicb.2018.01696. [36] OoiML, DrillingAJ, MoralesS, et al.Safety and tolerability of bacteriophage therapy for chronic rhinosinusitis due to Staphylococcus aureus[J].JAMA Otolaryngol Head Neck Surg,2019, 145(8):723-729. DOI: 10.1001/jamaoto.2019.1191. [37] FishR, KutterE, BryanD, et al.Resolving digital staphylococcal osteomyelitis using bacteriophage-a case report[J].Antibiotics (Basel),2018, 7(4):87. DOI: 10.3390/antibiotics7040087. [38] 胡福泉.噬菌体的过去、现在与未来[J].西南医科大学学报,2021,44(5):417-424.DOI: 10.3969/j.issn.2096-3351.2021.05.001. [39] RegeimbalJM, JacobsAC, CoreyBW, et al.Personalized therapeutic cocktail of wild environmental phages rescues mice from Acinetobacter baumannii wound infections[J].Antimicrob Agents Chemother,2016, 60(10):5806-5816. DOI: 10.1128/aac.02877-15. [40] GillJJ, HymanP.Phage choice, isolation, and preparation for phage therapy[J].Curr Pharm Biotechnol,2010, 11(1):2-14. DOI: 10.2174/138920110790725311. [41] KrupovicM,DutilhBE,AdriaenssensEM,et al.Taxonomy of prokaryotic viruses: update from the ICTV bacterial and archaeal viruses subcommittee[J].Arch Virol,2016,161(4):1095-1099.DOI: 10.1007/s00705-015-2728-0. [42] ŁobockaM,HejnowiczMS,DąbrowskiK,et al.Genomics of staphylococcal Twort-like phages--potential therapeutics of the post-antibiotic era[J].Adv Virus Res,2012,83:143-216.DOI: 10.1016/B978-0-12-394438-2.00005-0. [43] AzamAH, TanjiY.Peculiarities of Staphylococcus aureus phages and their possible application in phage therapy[J].Appl Microbiol Biotechnol,2019, 103(11):4279-4289. DOI: 10.1007/s00253-019-09810-2. [44] Głowacka-RutkowskaA, UlatowskaM, EmpelJ, et al.A Kayvirus distant homolog of staphylococcal virulence determinants and VISA biomarker is a phage lytic enzyme[J].Viruses,2020, 12(3):292. DOI: 10.3390/v12030292. [45] DonovanDM,LardeoM,Foster-FreyJ.Lysis of staphylococcal mastitis pathogens by bacteriophage phi11 endolysin[J].FEMS Microbiol Lett,2006,265(1):133-139.DOI: 10.1111/j.1574-6968.2006.00483.x. [46] PaulVD,RajagopalanSS,SundarrajanS,et al.A novel bacteriophage tail-associated muralytic enzyme (TAME) from Phage K and its development into a potent antistaphylococcal protein[J].BMC Microbiol,2011,11:226.DOI: 10.1186/1471-2180-11-226. [47] GuJM,XuW,LeiLC,et al.LysGH15, a novel bacteriophage lysin, protects a murine bacteremia model efficiently against lethal methicillin-resistant Staphylococcus aureus infection[J].J Clin Microbiol,2011,49(1):111-117.DOI: 10.1128/JCM.01144-10. [48] KaurJ, SinghP, SharmaD, et al. A potent enzybiotic against methicillin-resistant Staphylococcus aureus[J].Virus Genes,2020, 56(4):480-497. DOI: 10.1007/s11262-020-01762-4. [49] CahillJ, YoungR.Phage lysis: multiple genes for multiple barriers[J].Adv Virus Res,2019, 103:33-70. DOI: 10.1016/bs.aivir.2018.09.003. [50] LindenSB,ZhangH,HeselpothRD,et al.Biochemical and biophysical characterization of PlyGRCS, a bacteriophage endolysin active against methicillin-resistant Staphylococcus aureus[J].Appl Microbiol Biotechnol,2015,99(2):741-752.DOI: 10.1007/s00253-014-5930-1. [51] 高明明,刘慧莹,李璞媛,等.金黄色葡萄球菌噬菌体vB_SauH_IME522的分离鉴定及全基因组分析[J].第三军医大学学报,2020,42(3):229-240.DOI: 10.16016/j.1000-5404.201909016. [52] ShimamoriY, PramonoAK, KitaoT, et al. Isolation and characterization of a novel phage SaGU1 that infects Staphylococcus aureus clinical isolates from patients with atopic dermatitis[J].Curr Microbiol,2021, 78(4):1267-1276. DOI: 10.1007/s00284-021-02395-y. [53] Bailly-BechetM, VergassolaM, RochaE. Causes for the intriguing presence of tRNAs in phages[J].Genome Res,2007,17(10):1486-1495.DOI: 10.1101/gr.6649807. [54] NunesA, RibeiroDR, MarquesM,et al.Emerging roles of tRNAs in RNA virus infections[J].Trends Biochem Sci,2020,45(9):794-805.DOI: 10.1016/j.tibs.2020.05.007. [55] McCallinS, SarkerSA, BarrettoC,et al.Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects[J].Virology,2013,443(2):187-196.DOI: 10.1016/j.virol.2013.05.022. [56] QuirósP,Colomer-LluchM,Martínez-CastilloA,et al.Antibiotic resistance genes in the bacteriophage DNA fraction of human fecal samples[J].Antimicrob Agents Chemother,2014,58(1):606-609.DOI: 10.1128/AAC.01684-13. [57] 靳晓东,张聪慧,钟江.两株新的金黄色葡萄球菌烈性噬菌体的生物学特性和基因组学研究[J].微生物与感染,2018,13(6):335-341.DOI: 10.3969/j.issn.1673-6184.2018.06.003. [58] JiJW, LiuQ, WangR, et al. Identification of a novel phage targeting methicillin-resistant Staphylococcus aureus in vitro and in vivo[J].Microbial Pathogenesis,2020, 149:104317. DOI: https://doi.org/10.1016/j.micpath.2020.104317. [59] GutiérrezD, VandenheuvelD, MartínezB, et al.Two phages, phiIPLA-RODI and phiIPLA-C1C, lyse mono- and dual-species Staphylococcal biofilms[J].Appl Environ Microbiol,2015, 81(10):3336-3348. DOI: 10.1128/aem.03560-14. [60] FengTT, LeptihnS, DongK, et al. JD419, a Staphylococcus aureus phage with a unique morphology and broad host range[J].Front Microbiol,2021, 12:602902. DOI: 10.3389/fmicb.2021.602902. [61] DoubJB, NgVY, JohnsonAJ, et al.Salvage bacteriophage therapy for a chronic MRSA prosthetic joint infection[J].Antibiotics (Basel),2020, 9(5):241. DOI: 10.3390/antibiotics9050241. [62] JikiaD,ChkhaidzeN,ImedashviliE,et al.The use of a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infected local radiation injuries caused by exposure to Sr90[J].Clin Exp Dermatol,2005,30(1):23-26.DOI: 10.1111/j.1365-2230.2004.01600.x. [63] LuongT, SalabarriaAC, RoachDR.Phage therapy in the resistance era: where do we stand and where are we going?[J].Clin Ther,2020, 42(9):1659-1680. DOI: 10.1016/j.clinthera.2020.07.014. -
1 从1例胸骨正中切口感染患者创面标本中分离的耐甲氧西林金黄色葡萄球菌噬菌体SAP23及噬菌斑形态。1A.噬菌体SAP23形成透明噬菌斑 图中标尺为10 mm；1B.噬菌体SAP23头部为多面体，并有尾部 透射电子显微镜×40 000，图中标尺为40 nm
2 从1例胸骨正中切口感染患者创面标本中分离的耐甲氧西林金黄色葡萄球菌噬菌体SAP23基因注释记录图
注：每个箭头代表1个开放阅读框，不同颜色代表编码蛋白不同功能分类；GC为鸟嘌呤胞嘧啶
3 从1例胸骨正中切口感染患者创面标本中分离的耐甲氧西林金黄色葡萄球菌噬菌体SAP23基因组与6株葡萄球菌噬菌体基因组的全基因组共线性记录图
注：1.噬菌体SAP23，2.葡萄球菌噬菌体P108，3.葡萄球菌噬菌体812，4.葡萄球菌噬菌体VB_SavM_JYL02，5.葡萄球菌噬菌体VB_SavM_JYL01，6.葡萄球菌噬菌体vB_SauH_IME522，7.葡萄球菌噬菌体vB_ScoM-PSC1；5种颜色块代表5个局部共线区域；局部共线区域内部或外部的空白区域代表基因组之间的差异区域
4 从1例胸骨正中切口感染患者创面标本中分离的耐甲氧西林金黄色葡萄球菌噬菌体SAP23系统发生树记录图。4A.主要大衣壳蛋白氨基酸序列系统发生树；4B.全基因组序列系统发生树
注：系统发生树中括号中编号为GenBank登录号，左侧分支数据代表可信度
5 从1例胸骨正中切口感染患者创面标本中分离的耐甲氧西林金黄色葡萄球菌噬菌体SAP23与宿主菌共培养不同时间点的噬菌体效价（
注：PFU为菌斑形成单位；该图为经过lg处理的数据形成的描记图；坐标轴数据为未经lg处理的原始数据
6 从1例胸骨正中切口感染患者创面标本中分离的耐甲氧西林金黄色葡萄球菌噬菌体SAP23在不同温度和pH值条件下的稳定性（
注：PFU为菌斑形成单位；图6B为经过lg处理的数据形成的描记图，坐标轴数据为未经lg处理的原始数据
表1 胸骨正中切口感染患者耐甲氧西林金黄色葡萄球菌噬菌体SAP23对41株耐甲氧西林金黄色葡萄球菌裂解情况
菌株编号 噬菌斑 菌株编号 噬菌斑 菌株编号 噬菌斑 菌株编号 噬菌斑 DP100 - CY6 ++ NF99 - G15 - CY15 - NF7 - SY14 - G26 - CY14 - NF70 - SY19 - G25 - CY19 - NF71 - SY33 - G31 - CY18 - NF73 - SY17 ++ G34 - CY5 - NF75 - SY5 - G13 - CY11 - NF8 - SY13 - G21 - CY16 - NF84 - SY23 - G17 - CY7 - NF88 - SY6 - G36 - CY8 - NF90 + SY15 - G16 - CY20 - 注：“++”表示可见透明噬菌斑，“+”表示可见混浊噬菌斑，“-”表示未见噬菌斑 
下载: 导出CSV
-
图(6) / 表(1)
计量
- 文章访问数: 840
- HTML全文浏览量: 87
- PDF下载量: 44
- 被引次数: 0
